Siemens Healthcare plans to expand its portfolio of magnetic resonance imaging (MRI) systems to include the Magnetom Amira 1.5 Tesla system, which the company introduced at RSNA 2014.
CardioKinetix Inc. announced it has completed a $50 million financing led by Edwards Lifesciences Corp. with participation from other existing investors. This financing provides CardioKinetix with the capital necessary to complete the PARACHUTE IV randomized pivotal clinical trial of the Parachute ventricular partitioning device for the treatment of heart failure.

A study published in the Journal of the American College of Cardiology (JACC) shows intravascular near-infrared spectroscopy (NIRS) can identify lipid core-containing plaques, implicated in most heart attacks. The study shows the technology might be used as a means to predict the risk of future major adverse cardiac and cerebrovascular events (MACCE).
SPONSORED CONTENT — Studycast is a comprehensive imaging workflow system that allows healthcare professionals to work ...
CardioCell LLC announced the treatment of its first patient in the University of Pennsylvania’s Phase IIa clinical trial for chronic heart failure (HF) of non-ischemic cardiomyopathy.
Turner MedTech introduced ClearShield at RSNA, which is lead-free, eco-friendly, utilizes no lead and complies with European Union RoHS requirements.
COR Medical Technologies (COR) introduces CORcare, a comprehensive instant outcome support system for rapid and accurate diagnosis, treatment, and follow-up management of patients with acute and chronic, common and rare diseases involving the cardiovascular system.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Children’s hospitals in the United States delivering the highest-quality care for children undergoing heart surgery also appear to provide care most efficiently at a low cost, according to research led by the University of Michigan and presented at the American Heart Association Scientific Sessions in Chicago.
Researchers at the Minneapolis Heart Institute Foundation have found that when care teams started following a new set of guidelines for certain patients recovering from cardiovascular surgery, hospital stays (and the associated costs) were reduced.
Breathing secondhand marijuana smoke could damage heart and blood vessels as much as secondhand cigarette smoke, according to preliminary research presented at the American Heart Association’s Scientific Sessions 2014.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
BioCardia Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s application to begin a Phase III clinical trial of its bone marrow-derived CardiAMP Therapy for heart failure. The clinical trial is a randomized, controlled, multi-center study of 250 patients evaluating CardiAMP Therapy at up to 40 clinical sites.
Most patients with implantable cardioverter defibrillators (ICDs) haven’t thought about device deactivation if they were to develop a serious illness from which they were not expected to recover.
Researchers reported on a procedure that can preserve fertility and potentially save the lives of women with a serious pregnancy complication called placenta accreta. Results of the new study presented at the annual meeting of the Radiological Society of North America (RSNA) showed that placement of balloons in the main artery of the mother's pelvis prior to a Caesarean section protects against hemorrhage and is safe for both mother and baby.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
New research from the Minneapolis Heart Institute Foundation has uncovered a way to help interventional cardiologists better predict which patients are at higher risk for death following TAVR, allowing both patient and surgeon to discuss a potentially different treatment plan.
According to a new long-term study, diabetic patients with even mild coronary artery disease face the same relative risk for a heart attack or other major adverse heart events as diabetics with serious single-vessel obstructive disease.
Results from a new study indicate that the addition of mitral valve (MV) repair to coronary artery bypass grafting (CABG) did not result in significant benefit to the patient and was associated with increased risk of neurological events. Therefore, the routine addition of MV repair to CABG in patients with moderate ischemic mitral regurgitation (IMR) did not demonstrate a clinically meaningful advantage.